Literature DB >> 1183993

Pathology of high dose intermittent cyclophosphamide therapy.

R E Slavin, J C Millan, G M Mullins.   

Abstract

Pathologic changes induced by high dose intermittent cyclophosphamide therapy are described in 39 patients with solid tumors, lymphohematopoietic malignant disease, and bone marrow transplants. Patients receiving 50 to 120 mg. per kg. daily for one to four days showed transmural bladder injury affecting all component tissue; toxic vasculitis involving small arteries, capillaries, and venules; and interstitial, myocardial, and vascular changes in the heart. Myocardial necrosis with heart failure was the dose limiting factor of very high dose therapy. Patients receiving 15 to 30 mg. per kg. for four days showed variable degrees of bladder injury limited to the mucosa and lamina propria and vascular changes consisting only of telangiectasia. Both groups showed atypia of transitional urinary and esophageal epithelia as well as of mesenchymal cells in the lamina propria of the bladder, persistent and total ablation of spermatogenesis, and long lasting absence of ovarian follicular maturation. Bone marrow hypoplasia and lymphoid depletion developing after cyclophosphamide therapy completely disappeared an average of 3.5 weeks after the last dose.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1183993     DOI: 10.1016/s0046-8177(75)80078-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

Authors:  W P Peters; A Stuart; M Klotman; C Gilbert; R B Jones; E J Shpall; J Gockerman; R C Bast; J O Moore
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

3.  Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Authors:  Sulaiman Al-Hashmi; Zuzana Hassan; Behnam Sadeghi; Björn Rozell; Moustapha Hassan
Journal:  Int J Clin Exp Pathol       Date:  2011-07-31

Review 4.  Cardiotoxicity of cancer chemotherapy: implications for children.

Authors:  Valeriano C Simbre; Sarah A Duffy; Gul H Dadlani; Tracie L Miller; Steven E Lipshultz
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Metastasis of a transplantable mammary tumour in rats treated with cyclophosphamide and/or irradiation.

Authors:  J V Moore; B Dixon
Journal:  Br J Cancer       Date:  1977-08       Impact factor: 7.640

Review 6.  Cancer, chemotherapy and anaesthesia.

Authors:  F Chung
Journal:  Can Anaesth Soc J       Date:  1982-07

7.  Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis.

Authors:  Eun Kyung Kim; Gun Yoon; Hyun-Soo Kim
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

8.  Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.

Authors:  S Rosenow; K L Kooistra; G Powis; R A Van Dyke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.

Authors:  J P Eder; A D Elias; L Ayash; C A Wheeler; T C Shea; L E Schnipper; E Frei; K H Antman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.

Authors:  Tom McCulloch; Andrew Prayle; Andy Lunn; Alan R Watson
Journal:  Pediatr Nephrol       Date:  2011-03-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.